A Phase 1 interventional study of A (migalastat) and B (migalastat) in Fabry Disease, sponsored by Amicus Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-12-18.
Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.
Among the 20 studies testing migalastat in Fabry Disease, this one is the 10th largest by enrollment, is one of 5 that started in 2011, is one of 3 in phase 1, and was the 9th registered.
244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.
Browse Fabry Disease studies →2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:
Idorsia Pharmaceuticals Ltd. · Sites in United States, Canada, France and 2 more countries
Ages 18–60 · Men only
Amicus Therapeutics · Sites in United States, Belgium, Germany and 3 more countries
Ages 2–11
By country, each count listing its studies:
migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2011.
This study's enrollment of 20 is close to the median of 22 across 108 interventional studies indexed under Fabry Disease.
Median enrollment 20 across the 20 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 2 most frequent:
This study is registered under Amicus Therapeutics, one of the names counted as BioMarin Pharmaceutical. Under that name alone:
Amicus Therapeutics is the lead sponsor of 42 studies on the registry; 8 are open to participants now.
26 studies in Fabry Disease by BioMarin Pharmaceutical: 3 open now, 4 under way, 2 of them phase 3. Of 21 finished, 13 (62%) have results posted.
Among the 26 studies in Fabry Disease by BioMarin Pharmaceutical, this one is the 9th largest by enrollment of the 19 interventional ones that give a count, is one of 7 that started in 2011, is one of 5 in phase 1, and was the 9th registered.
BioMarin Pharmaceutical’s Fabry Disease studies by the year they started, since 2006.
1 of the studies testing migalastat in Fabry Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing migalastat in Fabry Disease, from their registry updates:
Among BioMarin Pharmaceutical’s 26 in Fabry Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A 5-period crossover study to evaluate the effect of meal type and timing on migalastat HCl pharmacokinetics in healthy male and female subjects. Subjects will be randomly assigned to 1 of 5 treatment sequences and will receive each treatment over the course of 5 weekly periods.
This is a Phase 1, randomized, open-label, 5-period crossover study to evaluate the effect of meal type and timing on migalastat HCl pharmacokinetics in healthy male and female subjects between the ages of 18 and 65 years. A total of 20 subjects will be enrolled such that approximately 14 evaluable subjects complete dosing and critical assessments. Subjects will be randomly assigned to 1 of 5 treatment sequences and will receive each treatment over the course of 5 successive weekly periods including a single dose of migalastat HCl 150 mg in the fasting state as the reference treatment. There will be at least a 7-day washout period between each dose of migalastat HCl and a follow-up visit approximately 7 to 10 days after the last dose in Period 5.
All subjects will be screened within 28 days of admission to the clinical unit. In each period, subjects will check in to the clinical unit the day prior to drug administration and have relevant assessments to ensure continued eligibility for dose administration. On Day 1 of each period, subjects will receive a single dose of migalastat HCl within 1 of the following 5 treatment regimens as follows:
Subjects will be confined to the clinical unit for 24 hours after dosing with serial blood samples collected for PK analysis. Safety will be assessed throughout the study by monitoring clinical laboratory tests, ECGs, physical examinations, vital signs, and AEs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fasted
Drug: A (migalastat)
Fed
Drug: B (migalastat)
Fed
Drug: C (migalastat)
Fed
Drug: D (migalastat)
Fed
Drug: E (migalastat)
150 mg migalastat HCl in the fasting state (reference arm)
150 mg migalastat HCl with simultaneous consumption of a glucose drink
150 mg migalastat HCl 1 hour before consumption of a high fat meal
150 mg migalastat HCl 1 hour before consumption of a light meal
150 mg migalastat HCl 1 hour after consumption of a light meal
Maximum observed plasma concentration of migalastat HCl after a single dose
Cmax
Time frame: 5 weeks (60 PK timepoints)
Time of occurence of maximum observed plasma concentration of migalastat HCl after a single dose
tmax
Time frame: 5 weeks (60 PK timepoints)
Area under the plasma concentration-time curve of migalastat HCl after a single dose from time 0 (before dosing) to infinity
AUC (0 to infinity)
Time frame: 5 weeks (60 PK timepoints)
Terminal phase half life of migalastat HCl after a single dose
t1/2
Time frame: 5 weeks (60 PK timepoints)
Apparent clearance following oral dosing of migalastat HCl after a single dose
CL/F
Time frame: 5 weeks (60 PK timepoints)
Area under the plasma concentration-time curve of migalastat HCl after a single dose from time 0 (before dosing) to the time of the last quantifiable concentration
AUC (0 to t)
Time frame: 5 weeks (60 PK timepoints)
Adverse Events
Time frame: 5 weeks
Clinical Laboratory Tests
Time frame: 5 weeks
Vital Signs
Time frame: 5 weeks
ECGs
Time frame: 5 weeks
Physical Examination
Time frame: 5 weeks
The record gives a start of Oct 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Migalastat